DIFFERENTIAL GENE EXPRESSION IN PHYSIOLOGICAL AND PATHOLOGICAL ANGIOGENESIS

摘要

#$%^&*AU2014200453B220150618.pdf#####ABSTRACT Methods of inhibiting pathological angiogenesis in a subject are disclosed. In particular examples, the method includes administering a therapeutically effective amount of a composition to a subject wherein the composition includes a specific binding agent that preferentially binds to one or more pathological angiogenesis marker proteins including Vscp, CD276, ETSvg4 (Pea3), CD137(4-1BB), MiRP2, Ubiquitin D (Fat 10), Doppel (prion-PLP), Apelin, Plgf, Ptprn (IA-2), CD1 09, Ankylosis, and collagen VIII1. In additional examples, methods to deliver a therapeutic agent to a brain or liver endothelial cell are also disclosed.